KR870008027A - Protocell immortalization - Google Patents

Abstract

No content

Description

Protocell immortalization

Since this is an open matter, no full text was included.

Claims (52)

(a) preparing normal, activated / stimulated progenitor cells; (b) the progenitor cells are transduced with an oncogenic DNA / oncogene, which is optionally composed by liposomes, by electroporation to produce transduced progenitor cells; (c) a method of producing immortalized primitive cell lines consisting of recovering immortalized primitive cell lines from such transfected primitive cells. The method of claim 1, wherein the tumorigenic DNA is genomic DNA from a progenitor tumor or a tumor progenitor cell line and the tumor or tumor cell line has an origin corresponding to an immortalized progenitor cell type. The method of claim 1, wherein the carcinogenic gene is from a progenitor cell tumor or from a tumor progenitor cell line and the tumor or tumor cell line has an origin corresponding to the progenitor cell type to be immortalized. The method of claim 2 wherein the original cell is of hematopoietic origin. The method of claim 3, wherein the progenitor cells are multipotent lineage cells, B-lymphocyte cells, B-line precursors, T-lymphocyte cells, T-line precursors, myeloid lineage cells, monocytes, neutrophils, eosinophils, megakaryocytes or mammary gland cells. The method of claim 4, wherein the progenitor cells are B-lymphocyte cells. The method of claim 5, wherein B lymphocyte cells are activated / stimulated with an antigen. The method of claim 5, wherein the oncogene is a Han-Ras oncogene or a P 53-H7 oncogene. The method of claim 6, which is genomic DNA of oncogenic DNA BJAB. The method of claim 6 wherein the oncogenic DNA is genomic DNA of a REH cell line. The method of claim 6 wherein the oncogenic DNA is genomic DNA of an EL4 cell line. Immortalized progenitor cell line produced by the method of claim 1. The cell line of claim 12, wherein the tumorigenic DNA is a progenitor tumor or a genomic DNA of a tumor progenitor cell, the gene of which corresponds to a progenitor cell form into which the tumor or tumor cell is to be immortalized. The cell line of claim 12, wherein the carcinogenic gene is obtained from a progenitor cell tumor from a tumor progenitor cell line and has a origin corresponding to the protocellular form from which the tumor or tumor cell line is to be immortalized. The cell line of claim 12, wherein the progenitor cells are of hematopoietic origin. The cell line of claim 15, wherein the progenitor cells are multipotent line cells, B-lymphocyte cells, B-line precursors, T-lymphocyte cells, T-line precursors, myeloid lineage cells, monocytes, neutrophils, eosinophils, megakaryocytes or mammary cells. The cell line of claim 16, wherein the original cell is a B-lymphocyte cell. The cell line of claim 17 activated / stimulated with B lymphocyte cell antigen. The cell line of claim 16, wherein the oncogene is a Ha-ras oncogene. The cell line of claim 16, wherein the oncogenic DNA is genomic DNA of BJAB. The cell line of claim 16, wherein the oncogenic DNA is genomic DNA of a REH cell line. The cell line of claim 16, wherein the oncogenic DNA is genomic DNA of an EL4 cell line. As a method for producing a biological product consisting of DNA contained in the cell line of the immortalized immortal array, (a) preparing normal, activated / stimulated progenitor cells; (b) transfecting the progenitor cells with an oncogenic DNA / oncogene (optionally composed of lysosomes) by electroporation to produce transduced progenitor cells; (c) recovering immortalized progenitor cell lines from the progenitor cells thus transduced; (d) culturing the immortalized cell line under conditions capable of producing a biological product. Next, a method for producing a transduced and immortalized progenitor cell line comprising an exogenous functional DNA sequence consisting of (a)-(c). (a) preparing normal, activated / stimulated progenitor cells; (b) co-transforming the progenitor cells into an oncogenic DNA / carcinogen and an exogenous functional DNA array (optionally composed of liposomes) by electroporation to produce cotransformed progenitor cells; (c) recovering from such cotransduced progenitor cells an immortalized progenitor cell line containing an exogenous functional DNA sequence. The method of claim 24, wherein the tumorigenic DNA is a progenitor tumor or genomic DNA of a tumor cell line and has a origin corresponding to the protocellular form from which the tumor or tumor cell line is to be immortalized. The method of claim 24, wherein the oncogene is from a progenitor tumor or a tumor progenitor cell line and has an origin corresponding to the progenitor cell form from which the tumor or tumor cell line is to be immortalized. The method of claim 24, wherein the original cell is a hematopoietic source. The method of claim 27, wherein the progenitor cells are multipotent lineage cells, B-lymphocyte cells, B-line precursors, T-lymphocyte cells, T-line precursors, myeloid lineage cells, monocytes, neutrophils, eosinophils, megakaryocytes, or mammary cells. The method of claim 28, wherein the progenitor cells are B-lymphocytes. The method of claim 29 activated / stimulated with B-lymphocyte cellocyte antigen. The method of claim 29, wherein the oncogene is a Ha-ras oncogene or a oncogene. The method of claim 29, wherein the tumorigenic DNA is genomic DNA of BJAB. The method of claim 29, wherein the tumorigenic DNA is genomic DNA of the REH cell line. The method of claim 29, wherein the tumorigenic DNA is genomic DNA of the EL4 cell line. A cotransduced and disrupted progenitor cell line produced by the method of claim 24. The cell line of claim 35, wherein the tumorigenic DNA is a progenitor tumor or a tumor cell line genomic DNA, and the tumor or tumor cell line has an origin corresponding to that of the original cell to be immortalized. The cell line of claim 35, wherein the oncogene is from a progenitor tumor cell line and has origins corresponding to the progenitor form in which such tumor or tumor cell line is to be immortalized. The cell line of claim 35, wherein the progenitor cell is a hematopoietic source. The cell line of claim 38, wherein the progenitor cells are multipotent lineage cells, B-lymphocyte cells, B-line precursors, T-lymphocyte cells, T-line precursors, myeloid lineage cells, monocytes, neutrophils, eosinophils, megakaryocytes, or mammary gland cells. The cell line of claim 39, wherein the progenitor cell is B-lymphocyte cell. The cell line of claim 40 activated / stimulated with B lymphocyte cell antigen. The cell line of claim 40, wherein the oncogene is a Ha-ras oncogene. The cell line of claim 40, wherein the oncogenic DNA is genomic DNA obtained from BJAB. The cell line of claim 40, wherein the oncogenic DNA is genomic DNA obtained from a REH cell line. The cell line of claim 40, wherein the oncogenic ONA is genomic ONA obtained from an EL4 cell line. A method of generating a biological product consisting of DNA contained within a cotransduced immortalized progenitor cell line that contains a foreign functional DNA array, wherein (a) preparing normal, activated / stimulated progenitor cells; (b) producing these progenitor cells co-transformed by electroporation into an oncogenic DNA / oncogene adventitious functional DNA array (optionally comprised of liposomes); (c) recovering the co-transformed, immortalized progenitor cell line containing the exogenous functional DNA sequence from such co-transformed progenitor cells; (d) A method comprising culturing such cotransduced and immortalized cell lines under conditions capable of producing these biological products. Immortalized progenitor cell line, provided that immortalization is a result of transduction by DNA consisting of the original carcinogenic gene of normal progenitor cells. 47. The cell line of claim 47, wherein the oncogene is from progenitor tumor progenitor cells and whose origin corresponds to the progenitor cell line from which the tumor or tumor cell line will be immortalized. The cell line of claim 47, wherein the progenitor cell is a hematopoietic source. The cell line of claim 49, wherein the progenitor cells are multipotent lineage cells, B-lymphocyte cells, B-line precursors, T-lymphocyte cells, T-line precursors, myeloid lineage cells, monocytes, neutrophils, eosinophils, megakaryocytes, or mammary gland cells. The cell line of claim 50, wherein the progenitor cell is B-lymphocyte cell. The cell line of claim 51, wherein the oncogene is a Ha-ras oncogene or a P53-7 oncogene. ※ Note: The disclosure is based on the initial application.